[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mood\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mood":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,45,84,118,152,189,224,252,278,303,327,359,381,407,431,456,485,508,534],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100641832","the-effect-of-reiki-applied-during-the-postpartum-period-on-the-quality-of-postpartum-recovery-comfort-and-mood-100641832",false,"NCT07654881","THE EFFECT OF REIKI APPLIED DURING THE POSTPARTUM PERIOD ON THE QUALITY OF POSTPARTUM RECOVERY, COMFORT AND MOOD.","THE EFFECT OF REIKI APPLIED DURING THE POSTPARTUM PERIOD (AFTER CESAREAN SECTION) ON THE QUALITY OF POSTPARTUM RECOVERY, COMFORT AND MOOD.","Inclusion Criteria:\n\n* Ages 19-35\n* Literate and able to communicate\n* Those who gave birth after 37 weeks of gestation\n* Those who had a single or intrauterine delivery\n* Those who meet the inclusion criteria and volunteer to participate\n* Those residing within the central district of Gaziantep province\n* Those who received spinal\u002Fepidural anesthesia\n\nExclusion Criteria:\n\n* Having an infectious skin disease\n* Having a chronic illness (diabetes mellitus, hypertension, etc.)\n* Having complications related to the birth process\n* The baby not being present for any reason\n* Using sedative agents for any reason\n* Mothers with disabled babies\n* Having experienced an acute psychiatric attack","FEMALE","19 Years","35 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","The postpartum period, also defined as the fourth trimester of pregnancy, encompasses the approximately 6-8 week period following childbirth, during which the organs that underwent changes during pregnancy return to their previous state. This period is of great importance in terms of protecting the health of both mother and baby, meeting their care needs, and increasing their comfort. During the postpartum period, women experience physiological, psychological, and social changes; hormonal changes, assuming parental roles, changes in family dynamics, and increased responsibilities related to infant care can lead to adjustment difficulties. This can cause problems for the mother in both her own care and infant care.\n\nIn the postpartum period, mothers may experience various health problems such as pain, fatigue, sleep disturbances, infections, breastfeeding problems, hemorrhoids, constipation, urinary incontinence, depressive symptoms, and mood swings. Pain, in particular, arises due to uterine contractions, breast engorgement, nipple tenderness, and other complications, negatively affecting the mother's mobility, sleep patterns, social interaction, and quality of life. Furthermore, stress and adjustment problems experienced during the postpartum period can lead to serious psychological problems such as delayed maternal bonding, postpartum blues, postpartum depression, psychosis, and communication problems between couples.\n\nPharmacological and non-pharmacological methods are used in the management of these problems. However, due to the negative effects that pharmacological methods may have during breastfeeding, interest in complementary and alternative medicine practices has increased. Reflexology, aromatherapy, music therapy, acupressure, and Reiki are among these methods.\n\nReiki is an energy therapy method that aims to balance an individual's life energy and support the natural healing process, applied through touch or the placement of hands on specific points. Reiki application is reported to have positive effects on pain, stress, anxiety, sleep quality, and coping skills. Although it is one of the preferred methods for adapting to changes and reducing problems experienced in the postpartum period, studies directly examining the effects of Reiki application on postpartum recovery quality, comfort, and mood are quite limited. Due to its low cost, ease of application, and lack of side effects, Reiki is considered an important complementary care approach that can be used in the postpartum period.\n\nThe aim of this study is to determine the effect of face-to-face Reiki treatment on the quality of postpartum healing, comfort level, and mood in women who have had cesarean deliveries, on days 1, 2, and 7 of the postpartum period.",[27,28,29,30],"Postpartum Period","Reiki Therapy","Mood","Comfort",[32],"Reiki Therapy, Postpartum Period, Mood, Comfort, Recovery of Function","NOT_YET_RECRUITING","2026-06-12",{"date":36,"type":37},"2026-06-17","ACTUAL",{"date":39,"type":21},"2026-06-15",{"date":41,"type":21},"2027-01-01",{"name":43,"class":44},"University of Gaziantep","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100643822","phase-1-psilocybin-efficacy-with-or-without-pimavanserin-pretreatment-100643822","NCT07610135","Psilocybin Efficacy With or Without Pimavanserin Pretreatment","PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment","PRISMatic","Inclusion Criteria:\n\n* Adults aged 21 to 65 years old\n* Fluency in English\n* At least high school level of education\n* Right-handed\n* Female participants of childbearing potential must agree to use a highly effective method of contraception throughout the study. Highly effective methods are defined as those that, when used consistently and correctly (alone or in combination), are associated with a failure rate of less than 1% per year. Condoms alone are not considered highly effective. Abstinence is not considered a highly effective method. However, at the investigator's discretion, abstinence may be accepted if, based on the investigator's judgment and knowledge of the participant's usual and preferred lifestyle, it can be reasonably expected to result in 100% effectiveness.\n* Agree to abstain from any psychoactive drugs on the day prior to and the day of the drug administration session as demonstrated by a negative toxicology report.\n* Agree to consume approximately the same amount of caffeine-containing beverage (e.g., coffee, tea) that he\u002Fshe consumes on a usual morning, before arriving at the research unit on the mornings of drug session days. If the participant does not routinely consume caffeinated beverages, he\u002Fshe must agree not to do so on session days.\n* Agree not to take any PRN medications on the mornings of drug sessions\n* Agree that for one week before the drug session, he\u002Fshe will refrain from taking any nonprescription medication, nutritional or herbal supplement except when approved by the study investigators. Exceptions will be evaluated by the study investigators and will include acetaminophen, non-steroidal anti-inflammatory drugs, and common doses of vitamins and minerals.\n\nExclusion Criteria:\n\n* Non-English speakers and those with language or hearing impairments\n* Left-handedness (assessed by the Edinburgh Handedness Inventory)\n* Any lifetime history of psychedelic use, including serotonergic compounds (e.g., psilocybin, LSD, mescaline, DMT, 5-MeO-DMT) and nontraditional psychedelics (e.g., MDMA, ketamine, ibogaine)\n* Presence of cardiac, pulmonary, vascular, renal, hepatic, or other significant medical comorbidities\n* Cardiovascular conditions: coronary artery disease, stroke, angina, uncontrolled hypertension (systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, and HR \\>90 bpm), a clinically significant ECG abnormality (e.g., atrial fibrillation), prolonged QTc interval (i.e., QTc \\> 450 msec), heart valve, or TIA in the past year\n* QTc interval prolongation exclusionary criteria: medications known to prolong the QT interval (including: Class 1A antiarrhythmics (e.g., quinidine, procainamide), Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotics (e.g., ziprasidone, chlorpromazine, thioridazine), certain antibiotics (e.g., gatifloxacin, moxifloxacin), subjects with congenital prolongation of the QT interval; subjects with family history positive for long QT syndrome; subjects with a history of cardiac arrhythmias; and subjects with history of any cardiovascular disorder\u002Fcondition known to increase the possibility of QT prolongation and torsades de pointes (i.e., symptomatic bradycardia, hypokalemia, hypomagnesemia, hypocalcemia, heart failure, or Brugada Syndrome).\n* Lifetime history of serious psychiatric or neurological disorders, including bipolar disorder, psychosis, or seizure disorder\n* Lifetime history of severe substance use disorder\n* Current (within past six months) substance use disorder of moderate or greater severity\n* Clinically significant suicidal ideation (with strong intent or means) within the past 6 months or lifetime history of suicide attempt, current suicidal ideation, or otherwise judged by a study clinician to be more than low risk for suicidality\n* Current use\u002Fpositive toxicology for illicit drugs at screening and prior to drug administration session (includes illicit, non-prescribed, or prohibited substances such as amphetamines, barbiturates, buprenorphine, benzodiazepines, cocaine, MDMA, methadone, opioids, phencyclidine (PCP), and tetrahydrocannabinol (THC))\n* Nicotine user consuming the equivalent of ≥ 10 cigarettes\u002Fday\n* Altered gastrointestinal anatomy \\[history of surgeries that promote a general intestinal malabsorption (e.g., jejunoileal bypass, jejunocolic bypass, roux-en-Y gastric bypass, vertical banded gastroplasty, gastric band, gastric stapling, sleeve gastrectomy, biliopancreatic diversion with partial gastrectomy, distal gastric bypass, duodenal switch)\\]\n* Weight \\\u003C 40kg\n* Have a first degree relative with schizophrenia or other psychotic disorders (except substance\u002Fmedication-induced or due to another medical condition), or bipolar I disorder\n* MRI contraindications (e.g., claustrophobia incompatible with MRI scanning, medical device or implant incompatible with MRI, prior history as a metal worker and\u002For certain metallic objects in the body). Must complete MRI screening form and be approved by MRI technologist before each scan.\n* Unable or unwilling to perform study procedures, or inappropriate for further study participation as determined by the PI and\u002For study clinicians",true,"ALL","21 Years","65 Years",{"count":58,"type":21},20,[60,61],"PHASE1","PHASE2","Twenty healthy adults (≥21 years old) will be enrolled to evaluate the efficacy of a single oral dose of psilocybin (25 mg) administered with or without pretreatment using oral pimavanserin (34 mg) or placebo. Outcome assessments will occur at 1 week and 1 month following psilocybin administration.\n\nThe purpose of this study is to clarify the receptor-level mechanisms underlying psilocybin's effects on mood and well-being, along with the associated neurophysiologic signatures. These mechanisms will be examined using psychometric scales, autonomic and fMRI-based neurophysiologic markers, and integrated pharmacokinetic\u002Fpharmacodynamic modeling.",[64,65,29,66],"Mood (Psychological Function)","Well Being","Healthy",[68,69,70,71,72,73],"Psilocybin","Randomized Controlled Trial","Tryptamine","Pimavanserin","Indoles","Indole Alkaloid","2026-06-04",{"date":76,"type":37},"2026-06-08",{"date":78,"type":21},"2026-07",{"date":80,"type":21},"2028-12",{"name":82,"class":44},"Johns Hopkins University",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":54,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100638866","effects-of-binaural-beats-and-spatialized-music-on-behavioural-and-psychological-symptoms-of-dementia-in-assisted-living-facility-residents-100638866","NCT07626944","Effects of Binaural Beats and Spatialized Music on Behavioural and Psychological Symptoms of Dementia in Assisted Living Facility Residents","Effects of Binaural Beats and Spatialized Music on Behavioural and Psychological Symptoms of Dementia in Assisted Living Facility Residents: A Randomized Controlled Pilot Protocol","Inclusion Criteria:\n\n* (1) age 55-95 years; (2) the subject and\u002For his\u002Fher legal guardian have signed written informed consent; (3) the subject is able to complete the entire trial period; and (4) a minimum of fifty percent of the subjects will have a diagnosis of a dementia condition with a moderate to severe progression.\n\nExclusion Criteria:\n\n* (1) profound hearing loss or impairment; (2) history of seizures, epilepsy (especially sound-induced epilepsy), claustrophobia, or other conditions that put the subject at risk during the trial; (3) physical or mental conditions that may result in inability to complete and\u002For affect the efficacy of assessment.","55 Years","95 Years",{"count":94,"type":21},120,[24],"The purpose of this study is to investigate the effects of Binaural Beat Music (BBM; personalized music playlist with binaural beats), Spatialized Music (SM; personalized and spatialized music playlist), their combination, and possible interaction on older adults in an assisted living community who are either living with a dementia diagnosis or are experiencing typical age-related changes. The control condition is a personalized music playlist without binaural beats and spatialization. It is hypothesized that BBM, SM, and their combination each improve aspects of BPSD compared to controls over a two-week intervention period.\n\nThe Specific Aims of the study are (1) to evaluate whether BBM, SM, and\u002For their combination is superior to control in reducing BPSD severity (primary outcome); (2) to evaluate whether BBM, SM, and\u002For their combination is superior to control in reducing caregiver distress (secondary outcomes); and (3) to evaluate the effects of BBM, SM, and\u002For their combination on improving overall well-being and mood (secondary outcomes).",[98,99,100,29],"BPSD","Caregiver Distress","Well-being",[102,100,29,99,103,104,105,106,69,107],"Dementia","Personalized Music Listening","Binaural Beat Stimulation","Spatial Audio","Artificial Intelligence","Assisted Living Residences","RECRUITING","2026-05-29",{"date":74,"type":37},{"date":112,"type":37},"2026-05-04",{"date":114,"type":21},"2026-06-27",{"name":116,"class":44},"Maharishi International University",2,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":53,"sex":16,"minAge":126,"maxAge":91,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":136,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":83},"100638243","impact-of-a-novel-functional-snack-on-perimenopausal-symptoms-and-well-being-100638243","NCT07599930","Impact of a Novel Functional Snack on Perimenopausal Symptoms and Well-being","Impact of a Novel Functional Snack on Perimenopausal Symptoms and Well-being: a Randomised, Double-blinded, Placebo-controlled, Crossover Trial","SWAP","Inclusion Criteria:\n\n* Adults aged 40 to 55\n* Score 14 or higher on the Menopause Rating Scale\n* For intervention purposes, eligible participants are also required to have a mobile phone and be able to read and speak English.\n\nExclusion Criteria:\n\n* People who consume more than 15g of fibre a day\n* People who consume more than 2 cups of coffee or tea a day\n* People who consume more than 4 portions (portion = 80g) of fruits and vegetables a day\n* People who do not have any intolerances or allergies to the following:\n* Any kinds of nuts including tree nuts, peanuts, hazelnuts and coconuts\n* Chia seeds\n* Pumpkin seeds\n* Sunflower seeds\n* Dates\n* Gluten\n* Dairy\n* Oats\n* Barley\n* Soya\n* People who smoke or vape or have smoked or vaped in the last 2 years\n* People who consume more than 21 drinks a week or have a history of excess alcohol intake\n* People with comorbid conditions that may limit participation in the study, such as a history of an acute cardiovascular event, including coronary artery disease, previous myocardial infarction (heart attack), stroke, peripheral artery disease, diabetes mellitus, chronic kidney disease, metabolic syndrome, malignancies, cardiac arrhythmia, renal failure, cardiac failure, uncontrolled hypertension, cancer or major psychiatric or cognitive problems\n* People receiving drug treatment for lipid metabolisms (e.g., statins)\n* People with a history of long-term use of medicines known to influence glucose metabolism (e.g., corticosteroids) or aspirin\n* People taking antihypertensive drugs\n* People who take antibiotics or bacterial agents (Probiotics) within 1 month\n* People who take vitamin\u002Fdietary supplements within 1 month\n* Pregnant women, women ready for pregnancy, and nursing mothers\n* cardiac arrhythmia\n* renal failure\n* heart failure (NYHA II-IV)\n* diabetes mellitus\n* Malignant disease\n* People who have participated in a biomedical study within the past 3 months\n* Women who require hormone replacement therapy during the development of the protocol.","40 Years",{"count":58,"type":21},[24],"This is a clinical trial aimed to investigate if a novel phytochemical and fibre-rich snack can improve perimenopausal symptoms and well-being in perimenopausal women aged 40-55 and not on hormone replacement therapy.\n\nHypothesis: The investigators hypothesise that the phytochemical and fibre-rich snack will improve perimenopausal symptoms via a gut microbiota mediated mechanism.\n\nMain research questions:\n\nDoes eating the snack every day lower menopause symptoms such as hot flushes, night sweats, mood changes, and sleep problems? Does the snack improve mood, stress, anxiety, sleep, and overall quality of life? Does the snack improve the balance of bacteria in the gut, and could this be part of how it helps symptoms?",[131,132,29,133,134,135],"Perimenopause","Perimenopause-Related Depression","Sleep","Quality of Life","Gut -Microbiota",[137,138,139,140,141,142],"phytochemical","fibre","mood","sleep","quality of life","gut","2026-05-14",{"date":145,"type":37},"2026-05-20",{"date":147,"type":37},"2026-04-24",{"date":149,"type":21},"2026-12",{"name":151,"class":44},"King's College London",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":54,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":172,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":187,"locationsCount":83},"100511439","impact-of-bright-light-therapy-on-prader-willi-syndrome-100511439","NCT05939453","Impact of Bright Light Therapy on Prader-Willi Syndrome","A Randomized, Double-Blind, Controlled Trial of Bright Light Therapy on All-Cause Excessive Daytime Sleepiness in Prader-Willi Syndrome","PWS-LT","Inclusion Criteria:\n\n* Diagnosis of PWS confirmed by genetic testing\n* Score of 12 or above on the Epworth Sleepiness Scale (ESS).\n\nExclusion Criteria:\n\n* Subjects with an eye condition that could be negatively affected by bright light such as patients with a history of retinal damage or patients needing photosensitizing medications\n* A history of previous treatment with LT\n* Patients presenting with active psychosis or mania","6 Years","88 Years",{"count":163,"type":21},50,[24],"This is a placebo controlled clinical trial to assess the utility of light therapy as a sufficient treatment for excessive daytime sleepiness in patients with Prader-Willi Syndrome",[167,168,169,170,29,171],"Prader-Willi Syndrome","Excessive Daytime Sleepiness","Hyperphagia","Body Weight","Behavior",[173,174,175,176,177,178,179,180],"Light Therapy","Aberrant Behavior Checklist","Clinical Global Impression- Improvement","Fitbit","Actigraphy reports","Epworth Sleepiness Scale","Hyperphagia Questionnaire (HQCT)","Modified Overt Aggression Scale (MOAS)","2026-05-13",{"date":183,"type":37},"2026-05-15",{"date":185,"type":37},"2023-10-01",{"date":149,"type":21},{"name":188,"class":44},"Maimonides Medical Center",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":53,"sex":54,"minAge":195,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":200,"conditions":201,"keywords":209,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":83},"100613449","pursuit-a-technologically-augmented-school-based-program-to-improve-child-coping-and-prevent-substance-use-100613449","NCT07266740","PURSUIT: A Technologically Augmented School-based Program to Improve Child Coping and Prevent Substance Use.","Inclusion Criteria:\n\n* Aged eight to 18 years\n* Enrolled in a Michigan elementary, middle, or high school\n\nExclusion Criteria:\n\n* Age under 8\n* Age over 18 years\n* Non-enrollment in A Michigan school.","8 Years","18 Years",{"count":198,"type":21},100,[24],"The study investigators aim to test an online support platform for Michigan youth aged 8-18 years enrolled in elementary, middle, or high school and their parent\u002Fcaregiver. The online support platform will be hosted on the Computerized Intervention Authoring System (CIAS) 3.0 and will provide evidence-based cognitive behavioral coping skills for physical (pain) and mental (stress, mood) health symptoms, with additional substance use prevention content for youth aged 12 and older. Evaluations will occur at baseline and then a post assessment approximately 8 weeks later.",[202,203,29,204,205,206,207,208],"Pediatric Pain","Anxiety","Stress","Feasibility Studies","Acceptability","Health Promotion","Online Mental Health Program",[210,211,212,204,213,203,29,214],"Cognitive-behavioral","School","Pediatrics","Pain","Substance use","2026-05-05",{"date":217,"type":37},"2026-05-07",{"date":219,"type":21},"2026-05-01",{"date":221,"type":21},"2026-10",{"name":223,"class":44},"Michigan State University",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":53,"sex":54,"minAge":196,"maxAge":56,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":233,"briefSummary":234,"conditions":235,"keywords":239,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":83},"100610548","effects-of-a-collagen-supplement-on-quality-of-life-appetite-and-glycaemic-control-100610548","NCT07229014","Effects of a Collagen Supplement on Quality of Life, Appetite and Glycaemic Control","Effects of a Collagen Supplement on Quality of Life, Appetite and Glycaemic Control: a Randomised, Double-blinded, Placebo-controlled, Crossover Trial in Overweight and Obese Adults.","GluCol","Inclusion Criteria:\n\n1. Subject is a healthy (as assessed by medical history) male or female adult, aged 18-65 years and overweight or obese (BMI 25 - 40 kg\u002Fm2).\n2. Subject has an impaired quality of life, as determined by scoring at least a total of 9 on the following questions:\n\n   1. In the past 4 weeks, did you feel you had a lot of energy? All of the time (1), most of the time (2), a good bit of the time (3), some of the time (4), a little of the time (5), and none of the time (6) (number 27 from SF-36 questionnaire) Version 3.0 \\[01\u002F10\u002F2025\\] Page 11 of 20\n   2. In the past 4 weeks, have you felt calm and peaceful? All of the time (1), most of the time (2), a good bit of the time (3), some of the time (4), a little of the time (5), and none of the time (6) (number 26 from SF-36 questionnaire)\n   3. In the past 2 weeks, did you have any difficulties with sleeping? Not at all (1), small amounts (2), moderate amounts (3), a great deal (4), an extreme amount (5), all the time (6) (number 3 from WHOQoL-100)\n3. Participant has an email address, internet access, a compatible smartphone and is willing and able to maintain internet access throughout the trial to complete virtual visits via video conference and to engage with mobile apps to answer electronic questionnaires.\n4. Subject is willing and able to comply with all study procedures, including consumption of the supplement daily, CGM use for 22 days total (2 x 11 days), complete standardised meal tests, and fill out health questionnaires.\n5. Subject is willing to take a supplement of bovine animal origin.\n6. Openness to participate in an online interview at the end of the study.\n\nExclusion Criteria:\n\n1. Participant has a history or presence of uncontrolled and\u002For clinically important pulmonary, cardiac, hepatic, renal, endocrine (including type 1 and 2 diabetes), hematologic, immunologic, neurologic (e.g., Alzheimer's or Parkinson's diseases), psychiatric (including unstable depression and\u002For anxiety disorders) or biliary disorders.\n2. Participant has a clinically important gastrointestinal (GI) condition that would potentially interfere with the evaluation of the study product \\[e.g., inflammatory bowel disease, irritable bowel syndrome, chronic constipation, severe constipation (in the opinion of the investigator), history of frequent diarrhoea, history of surgery for weight loss, gastroparesis, systemic disease that might affect gut motility according to the investigator, medication managed reflux and\u002For clinically important lactose intolerance.\n3. Participant has a history of chronic insomnia (defined as insomnia at least 3 d\u002Fweek over the past month), a diagnosed sleep disorder (e.g., OSA), or a chronic medical condition that may impact energy\u002Ffatigue levels, in the judgment of the investigator.\n4. Participant is a female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period. The method of contraception must be recorded.\n5. Participant has a known allergy, intolerance, or sensitivity to any of the ingredients in the study product, including bovine animal products.\n6. Participant has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer.\n7. Participant has experienced any major trauma or any other surgical event within three months of Virtual Visit 1.\n8. Participant has unstable use of a medication or supplement that the investigator considers may affect the outcomes of the trial.\n9. Participant is currently in another biomedical research study or has been in the 30 days before screening.\n10. Participant is an employee of, or has a financial interest in Darling Ingredients Inc.\n11. The individual has a condition the investigator believes would interfere with his ability to provide informed consent and to comply with the study protocol, which might confound the interpretation of the study results, or put the participant at undue risk.\n12. Participant is a vegan or vegetarian or excludes bovine products for cultural or religious reasons.",{"count":198,"type":21},[24],"This is a clinical trial aimed to investigate if a collagen supplement can improve quality of life, appetite and blood sugar in overweight and obese adults aged 18-65.\n\nHypothesis: Consumption of a collagen supplement for 8 days will improve quality of life and improve glycaemic control in comparison with a placebo in individuals overweight or with obesity with a perceived low quality of life.\n\nParticipants will be asked to:\n\n1. Consume a collagen peptide supplement for a total of 8 days at a time\n2. Fill in questionnaires about quality of life, appetite, mood and energy\n3. Wear continuous glucose monitors",[134,236,133,29,237,238],"Appetite","Energy","Blood Glucose Profile",[240,241,242,243,139,140],"collagen","glucose","appetite","statiety","2025-11-13",{"date":246,"type":37},"2025-11-14",{"date":248,"type":21},"2025-12",{"date":250,"type":21},"2027-01",{"name":151,"class":44},{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":53,"sex":259,"minAge":196,"maxAge":18,"enrollmentInfo":260,"targetDuration":4,"studyType":22,"phases":262,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":83},"100605770","exploring-the-cognitive-benefits-of-a-blackcurrant-based-supplement-in-normobaric-hypoxia-100605770","NCT07166835","Exploring the Cognitive Benefits of a Blackcurrant-Based Supplement in Normobaric Hypoxia","The Efficacy of a Blackcurrant-based Nootropic Drink to Support Cognitive Functioning Under Normobaric Simulated High Altitude","Inclusion Criteria:\n\n* Willing and able to provide written informed consent (in English)\n* Aged 18-35\n* Male\n* Residing at a low altitude (\\\u003C500m)\n\nExclusion Criteria:\n\n* Diagnosed food allergy or intolerance to the investigational products or control products. (Blackcurrant, food allergen\u002F pine, tree-derived allergen\u002F l-theanine tree allergen (camellia sinensis))\n* Significant past medical and psychiatric history and ongoing chronic conditions such as, cardiovascular disease, respiratory disease, endocrine disorder (e.g. Diabetes mellites) and neurological and psychiatric conditions including brain injury or are colourblind.\n* Significant medication history or current prescription of medication or supplements known to affect cognition such as. Sedatives, stimulants, or herbal supplements high in anthocyanin and polyphenol content.\n* A positive result from the pre-screening sickle cell trait blood test.\n* An abnormal ECG reading.\n* A resting heart rate above 100bmp.\n* A blood pressure reading above 140\u002F90mmHg.\n* Subjects not willing and\u002F or not able to comply with the scheduled visits required for the study.\n* Not willing to provide blood samples.\n* Not classified as low risk based on the ACSM guidelines.","MALE",{"count":261,"type":21},27,[24],"This study investigates the cognitive effects of Ārepa, a blackcurrant-based drink, under simulated high-altitude conditions (4,500m normobaric hypoxia for \\~180 minutes). Using a double-blind, randomised, placebo-controlled crossover design, participants will consume either the nootropic blackcurrant-based drink or a taste-matched placebo. Cognitive testing (\\~80 minutes) includes Trail-making, Stroop, N-back, Serial 7s\u002F3s, and RVIP tasks. Physiological measures (heart rate, SpO₂, blood) and biomarkers (MAO-B, BDNF, hsCRP, S100B, Prolactin, C3G, Sarmentosin) will be assessed. Scales will evaluate mood, wellbeing, and perceived effects. The aim is to determine if the nootropic drink can support cognitive function in hypoxic environments.",[265,266,267,268,29],"Cognitive Performance","Executive Function (Cognition)","Working Memory","Hypoxia Induced Cognitive Impairment","2025-09-03",{"date":271,"type":37},"2025-09-10",{"date":273,"type":21},"2025-09-01",{"date":275,"type":21},"2027-10-01",{"name":277,"class":44},"Leeds Beckett University",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":53,"sex":54,"minAge":196,"maxAge":56,"enrollmentInfo":285,"targetDuration":4,"studyType":22,"phases":287,"briefSummary":289,"conditions":290,"keywords":292,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":83},"100594252","early-phase-1-combined-blood-pressure-medication-and-activity-scheduling-for-low-mood-100594252","NCT07017023","Combined Blood Pressure Medication and Activity Scheduling for Low Mood","Cognitive Effects of Losartan-augmented Behavioural Activation in Anhedonia","Inclusion Criteria:\n\n* Willing and able to provide informed consent\n* Aged 18-65 years\n* Self-reported low levels of positive mood\n* Sufficient written and spoken English skills to understand study procedures\n* Normal or corrected to normal vision and hearing\n* Access to a computer and reliable internet connection\n\nExclusion Criteria:\n\n* Antidepressant treatment or medication in last three months\n* Currently receiving cognitive-behavioural therapy with behavioural activation\n* History of psychosis or bipolar disorder\n* History of substance dependence\n* Use of illegal drugs in last 3 months\n* First-degree relative with history of psychosis or bipolar disorder\n* Current or past hospitalisation for mental health reasons\n* BDI-II score \\>30\n* Judged to be currently at clinical risk of suicide\n* Past suicide attempt\n* CNS-medication last 6 weeks (including in another study)\n* Severely underweight or overweight in a manner that renders them unsuitable for the study in the opinion of the study medic\n* Current blood pressure or other heart medication\n* Diagnosis of intravascular fluid depletion or dehydration\n* History of angioedema\n* Impaired kidney function (based on self-report)\n* Very low blood pressure following established definitions (at least three consecutive measurements of blood pressure under standardised conditions where either the systolic or the diastolic blood pressure or both are below 90\u002F60 mmHg (in accordance with established standard definitions: https:\u002F\u002Fwww.nhs.uk\u002Fcond...-pressure-hypotension\u002F)\n* Current diagnosis of a developmental disorder (e.g. ADHD, Tourette's syndrome, severe learning disability) according to self-report, where in the opinion of the study team such difficulties would likely interfere with compliance or task performance\n* Current diagnosis of a neurological disorder (e.g. epilepsy, MS) according to self-report\n* Lifetime history of systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may put the participant at risk when participating, or may influence compliance or task performance\n* Pregnancy (urine pregnancy test during Baseline Visit), breast feeding or plans to become pregnant during study participation\n* Heavy use of cigarettes (smoke \\> 20 cigarettes per day)\n* Severe lactose intolerance (due to losartan containing some lactose monohydrate)",{"count":286,"type":21},76,[288],"EARLY_PHASE1","This study explores the effects of 7-day losartan (50mg) versus placebo with brief behavioural activation on emotional processing in young volunteers low in positive mood",[291,29],"Emotional Processing",[293,139],"emotional processing","2025-07-23",{"date":296,"type":37},"2025-07-24",{"date":298,"type":37},"2025-07-08",{"date":300,"type":21},"2026-12-31",{"name":302,"class":44},"University of Oxford",{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":54,"minAge":195,"maxAge":311,"enrollmentInfo":312,"targetDuration":4,"studyType":22,"phases":314,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":83},"100595484","developing-resilience-and-anxiety-management-through-the-arts-100595484","NCT07033052","Developing Resilience and Anxiety Management Through the Arts","Developing Resilience and Anxiety Management Through the Arts (DRAMA) 2","DRAMA","Inclusion Criteria:\n\n* Between 8 and 17 years of age\n* Individuals must have parental\u002Fguardian consent\n* Elevated levels of anxiety or depression based on\n\n  1. Screen for Child Anxiety Related Disorders (SCARED) score of 15 or higher, or;\n  2. Revised Children's Anxiety and Depression Scale (RCADS) Depression T score of 65 or higher, or;\n  3. Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS) clinician severity rating of 3 on any anxiety disorder or on a mood-related disorder\n\nExclusion Criteria:\n\n* Diagnosed with Conduct Disorder or with behavioral symptoms that would make it difficult for the child\u002Fadolescent to participate in the group or comply with directions given by the group leader (such as difficulty following instructions, difficulty staying in one's seat, defiance of adults, harming animals or people, threatening others, getting into physical fights, hyperactivity, impulsivity, difficulty waiting for one's turn, etc.)\n* Autism or developmental delays\n* Psychotic symptoms or active suicidality\n* Active Eating Disorders that raise concerns about morbidity and therefore need to be addressed in an intervention and actively monitored\n* Unsteady dosage or recently or impending changes to psychotropic medication(s)\n* Non-English-speaking individuals\n* Wards of the State","17 Years",{"count":313,"type":21},110,[24],"The Developing Resilience and Anxiety Management Through the Arts (DRAMA) Study examines the degree to which the arts can help to address stress, anxiety, and sad mood in children and adolescents. The researchers will pair theatrical improvisation exercises with cognitive-behavioral therapy (CBT) techniques versus improvisation exercises alone versus a social craft group on reducing elevated levels of anxiety and depression.",[203,317,29],"Depression","2025-07-16",{"date":320,"type":37},"2025-07-20",{"date":322,"type":37},"2025-04-15",{"date":324,"type":21},"2027-07-01",{"name":326,"class":44},"Case Western Reserve University",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":53,"sex":54,"minAge":333,"maxAge":334,"enrollmentInfo":335,"targetDuration":4,"studyType":22,"phases":337,"briefSummary":338,"conditions":339,"keywords":343,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":83},"100596564","investigation-of-the-acute-effects-of-nepalese-pepper-extract-zanthoxylum-armatum-dc-on-cognitive-function-mood-and-gaming-performance-in-young-healthy-competitive-gamers-100596564","NCT07047105","Investigation of the Acute Effects of Nepalese Pepper Extract (Zanthoxylum Armatum DC) on Cognitive Function, Mood and Gaming Performance in Young, Healthy, Competitive Gamers","Inclusion Criteria:\n\n* Aged 16 to 34 years inclusive\n* Males and females\n* Self-report of good health\n* Usually a regular (at least once per week) player of competitive multiplayer games, (prospective participants will be asked to contact the researchers to discuss their gaming habits if uncertain that they meet the criteria).\n\nExclusion Criteria:\n\n* Have any pre-existing medical condition\u002Fillness which will impact taking part in the study (i.e. participants may be allowed to progress to screening if they have a condition\u002Fillness which would not interact with the active treatments or impede performance).\n* Are currently taking prescription medications NOTE: the explicit exceptions to this are contraceptive treatments for female participants, and those taken 'as needed' in the treatment of asthma and hay fever. There may be other instances of medication use which, where no interaction with the active treatments is likely, and which would not be expected to have any impact on brain function, participants may be able to progress to screening.\n* Have high blood pressure (systolic over 139 mm Hg or diastolic over 89 mm Hg); or have low blood pressure (systolic below 90 mm Hg or diastolic below 60 mm Hg)\n* Have a Body Mass Index (BMI) outside of the range 18.5-35 kg\u002Fm2\n* Are pregnant, seeking to become pregnant or lactating\n* Have learning and\u002For behavioural diagnoses such as dyslexia or ADHD\n* Have a visual impairment that cannot be corrected with glasses or contact lenses (including colour-blindness)\n* Smoke tobacco or vape nicotine or use nicotine replacement products\n* Excessive caffeine intake (\\> 500 mg per day). If participants consume energy drinks they will be asked to refrain from this for 24 hour prior to attending testing.\n* Have relevant food intolerances\u002Fsensitivities, including caffeine sensitivity.\n* Have taken antibiotics within the past 4 weeks\n* Have taken dietary supplements e.g. Vitamins, omega 3 fish oils etc. in the last 4 weeks (Note: participation is possible following a 4-week supplement washout prior to participating and for the duration of the study on the proviso that the supplements they are taken are out of choice and not medically prescribed or advised)\n* Have any health condition that would prevent fulfilment of the study requirements (this includes non-diagnosed conditions for which no medication may be taken)\n* Are unable to complete all of the study assessments\n* Are currently participating in other clinical or nutrition intervention studies, or have done so in the past 4 weeks\n* Has been diagnosed with\u002F undergoing treatment for alcohol or drug abuse in the last 12 months\n* Have been diagnosed with\u002F undergoing treatment for a psychiatric disorder in the last 12 months\n* Suffers from frequent migraines that require medication (more than or equal to 1 per month)\n* Sleep disorders or are taking sleep aid medication\n* Any known active infections\n* Are non-compliant with regards treatment consumption","16 Years","34 Years",{"count":336,"type":21},60,[24],"The goal of this clinical trial is to learn if a Nepalese Pepper Extract (Zanthoxlum Armatum, ZA) supplement can improve cognitive performance and mental abilities in competitive gamers aged 16 to 34. The main questions it aims to answer are:\n\n1. Does ZA supplement improve cognitive abilities like attention, memory, and decision-making?\n2. What is the most effective dose of ZA supplement (300mg vs 150mg)?\n3. How do the effects of ZA supplement compare to caffeine?\n\nResearchers will compare four different treatments (high-dose ZA, low-dose ZA, caffeine, and placebo) to see if ZA supplement produces better cognitive performance than placebo and how it compares to caffeine\\*\\*.\n\nParticipants will:\n\n* Complete a screening visit with health checks and training on computer tasks\n* Attend four testing visits (7-14 days apart) where they receive different treatments\n* Avoid alcohol and energy drinks for 24 hours before each visit, and caffeine from waking\n* Take assigned treatment at 11:30am and complete cognitive tests at -1, 1, 3, and 5 hours in relation to dose.\n* Complete mood questionnaires, sleep assessments, and gaming-specific tasks (aim training, character control)\n* Wear heart rate monitors during testing\n* Eat standardized meals provided during visits\n* Play competitive games at home in the evening and complete performance questionnaires",[340,29,341,342],"Cognition","Gaming Performance","Fatigue",[340,29,344,345,346,347,348,349,342],"Gaming","Performance","Esports","Nepalese Pepper","Timut Pepper","Zanthoxylum Armatum","2025-06-23",{"date":352,"type":37},"2025-07-02",{"date":354,"type":37},"2025-06-13",{"date":356,"type":21},"2026-05",{"name":358,"class":44},"Northumbria University",{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":53,"sex":54,"minAge":366,"maxAge":56,"enrollmentInfo":367,"targetDuration":4,"studyType":22,"phases":369,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":379,"locationsCount":83},"100480892","use-muscadine-wine-nutraceuticals-to-improve-brain-health-cognition-and-mental-health-100480892","NCT05541887","Use Muscadine Wine Nutraceuticals to Improve Brain Health, Cognition, and Mental Health","Acute and Chronic Impacts of Muscadine Wine Polyphenols on Cognition, Memory, Mood, and Anxiety in Adults Over 50 Years of Age","Inclusion Criteria:\n\n* Healthy\n* BMI (18.5-29.9)\n* Body weight ≥110 pounds\n\nExclusion Criteria:\n\n* Pregnancy\n* Breast-feeding\n* Smokers\n* Diabetic\n* Heavy drinkers\n* Subjective but not clinically diagnosed cognitive impairment (Montreal cognitive assessment score \\\u003C26),\n* Inability to understand the cognitive function tasks\n* Intake of medication that might influence the outcome of the study (e.g. psychostimulant)\n* cannabis product user\n* Clinically diagnosed mental illnesses\n* Cardiovascular and neurological disorders\n* Uncontrolled hypertension","50 Years",{"count":368,"type":21},25,[24],"Previous studies have shown that polyphenol-rich foods can positively affect cognitive functions, memory, and mood in humans. We hypothesize that both acute and chronic intake of muscadine wine polyphenols will improve cognitive performance and mood through regulating the HPA axis, alleviating inflammation and oxidative stress, and\u002For inhibiting monoamine oxidase activities",[265,372,29,203],"Memory","2025-06-09",{"date":375,"type":37},"2025-06-12",{"date":377,"type":37},"2023-08-30",{"date":149,"type":21},{"name":380,"class":44},"University of Florida",{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":53,"sex":54,"minAge":196,"maxAge":388,"enrollmentInfo":389,"targetDuration":4,"studyType":22,"phases":391,"briefSummary":392,"conditions":393,"keywords":397,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":83},"100576091","investigating-the-acute-and-chronic-effects-of-a-supplement-containing-caffeine-vitamins-minerals-and-botanical-extracts-on-cognition-sleep-and-wellbeing-in-healthy-volunteers-100576091","NCT06780774","Investigating the Acute and Chronic Effects of a Supplement Containing Caffeine, Vitamins, Minerals and Botanical Extracts on Cognition, Sleep and Wellbeing, in Healthy Volunteers","Investigating the Acute and Chronic Effects of a Supplement Containing Caffeine, Vitamins, Minerals and Botanical Extracts on Cognition, Sleep and Wellbeing, in Healthy Volunteers.","Inclusion Criteria:\n\n* You self-assess yourself as being in good health.\n* You are aged 18-75 years at the time of giving consent.\n* English is your first language or are fluent in English.\n\nExclusion Criteria:\n\n* Insufficient (\\\u003C 40 mg per day) or excessive (\\> 500 mg per day) habitual caffeine consumption (\\* NOTE: This will be calculated at screening but feel free to query this with the researcher prior to attendance.).\n* Have any pre-existing medical conditions\u002Fillnesses which will impact taking part in the study. (\\* NOTE: The explicit exceptions to this are controlled hyper\u002Fhypothyroidism, hay fever, high cholesterol and reflux-related conditions. NOTE: There may be other, unforeseen, exceptions and these will be considered on a case-by-case basis, i.e. participants may be allowed to progress to screening if they have a condition\u002Fillness which would not interact with the active treatments or impede performance so it's worth discussing any medical conditions with the researcher prior to booking lab appointments).\n* Are currently taking prescription medications which will impact taking part in the study (\\* NOTE: the explicit exceptions to this are contraceptive treatments for female participants, thyroid medications, topical skin treatments and those medications used in the treatment of high cholesterol and reflux-related conditions; and those taken 'as needed' in the treatment of asthma and hay fever.).\n* Have high blood pressure (systolic over 139 mm Hg or diastolic over 89 mm Hg1) - \\*NOTE: We must measure this in the lab using our blood pressure monitors and can only use our measurements to access eligibility rather than home or GP readings.\n* Have a Body Mass Index (BMI) outside of the range 18.5-39.9 kg\u002Fm2.\n* Are pregnant, seeking to become pregnant or lactating.\n* Have been diagnosed with a neurological condition or assessed as having a learning\u002Fbehavioural or neurodevelopmental difference (e.g. dyslexia, autism, ADHD).\n* Have a visual impairment that cannot be corrected with glasses or contact lenses (including colour-blindness).\n* Smoke tobacco\u002F vape nicotine\u002F use nicotine replacement products (\\* NOTE: If participants have recently quit smoking or using replacements, they must have stopped using them altogether for a period of 3 months before participating in this study).\n* Have relevant food allergies\u002F intolerances\u002F sensitivities (Please discuss all allergies\u002F intolerances\u002F sensitivities with the researcher prior to your screening appointment).\n* Have taken antibiotics within the past 4 weeks.\n* Are currently consuming any other dietary supplement (e.g., vitamins, omega 3 fish oils etc.) or have done so in the last 4 weeks. (\\* NOTE: Participation is possible following a 4-week supplement wash out prior to participating and for the duration of the study on the proviso that the supplements they are taking are out of choice and not medically prescribed or advised. Please discuss with the researcher if unsure. NOTE: We would never advise stopping supplements prescribed by your doctor e.g., iron, calcium etc., only those you use out of choice).\n* Have any health conditions that would prevent the fulfilment of the study requirements (this includes non-diagnosed conditions for which no medication may be taken).\n* Are unable to complete all of the study assessments (this will be assessed by the researcher at your training appointment, whereby you must be able to reach the minimum scores for each cognitive task to progress with the trial).\n* Are currently participating in another clinical or nutrition intervention study or have done so in the past 4 weeks.\n* Have been diagnosed with\u002F undergoing treatment for alcohol or drug abuse in the last 12 months.\n* Have been diagnosed with\u002F undergoing treatment for a psychiatric disorder in the last 12 months, including a medical diagnosis of anxiety or depression.\n* Suffer from frequent migraines that require medication (more than or equal to 1 per month).\n* Have any sleep disorders or take any sleep aid medications.\n* Have any known active infections.\n* Will be non-compliant with regards to treatment consumption.\n* Does not have a bank account (required for payment).","75 Years",{"count":390,"type":21},90,[24],"The aim of the study is to investigate the acute and chronic effects of a supplement containing Caffeine, Vitamins, Minerals and Botanical extracts on cognitive function, sleep and wellbeing, in healthy volunteers.\n\nThe study will follow a randomised, double-blind, placebo-controlled, crossover design. Participants will receive both treatments, and both study arms will include an acute testing visit (day 1) and a chronic testing visit (day 29). The active treatment contains a blend of 120mg caffeine, vitamins, minerals and botanical extracts and the matched placebo treatment contains marigold extract and brown rice flour.\n\nThe trial will use computerised cognitive tasks, administered via COMPASS software (Northumbria University, UK), online cognitive assessments via Cognimapp and self-reported questionnaires and sleep diary, as measures of the outcome variables.\n\n90 participants will participate, aged 18-75, and self-ported as being in good health. Participants will be randomly allocated to a treatment order and will be supplied with either the active treatment or the placebo whilst visiting the research centre for the acute testing visits. Participants will take the treatment home to consume daily for the duration of the supplementation period. Participants will record the time of taking treatment each day in a treatment diary which will be returned to the research centre, along with any unused treatment, at each chronic testing visit.",[394,133,395,396,29],"Caffeine","Cognitive Function","Wellbeing",[394,398,133,396,29],"Cognitive function","2025-02-06",{"date":401,"type":37},"2025-02-10",{"date":403,"type":21},"2025-02-24",{"date":405,"type":21},"2025-12-19",{"name":358,"class":44},{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":53,"sex":16,"minAge":413,"maxAge":91,"enrollmentInfo":414,"targetDuration":4,"studyType":22,"phases":416,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":83},"100571154","efficacy-and-safety-of-shatavari-for-treatment-of-menopausal-symptoms-in-women-a-randomized-double-blind-three-arm-parallel-placebo-controlled-study-100571154","NCT06716554","Efficacy and Safety of Shatavari for Treatment of Menopausal Symptoms in Women: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study","Inclusion Criteria:\n\n1. Menopausal women aged 45 to 65 years with intact uterus and ovaries.\n2. Participants who complained of irregular menstrual cycle in the past 12 months, with a forward or postpone of a cycle more 7 days. At least 2 cycles were missing during the past 12 months, or reported menopause for at least 60 days\n3. Females with complaints of menopausal symptoms, e.g., hot flash, insomnia, migraine, easy irritation, etc.\n4. Body mass index 18-35 kg\u002Fm2\n5. Subject who has given written informed consent to participate in the study and understand the nature of the study\n6. Able to read and write in English or any other vernacular language\n7. No plan to commence new treatments over the study period.\n8. Must have the ability and willingness to sign an informed consent and to comply with all study procedures.\n\nExclusion Criteria:\n\n1. Participants taking any form of herbal extract in the last 3 months before study entry.\n2. Participants who are on hormone replacement therapy (HRT) for more than 3 months.\n3. Participants with Present active medical, surgical, and gynaecological problems.\n4. Participants with a history of alcohol, tobacco dependence, or any substance abuse\n5. Participants who had undergone bilateral ovariectomy\n6. Participants with history of breast or cervical carcinoma\n7. Participants who taking medication that affect bone metabolism, including glucocorticoid, anticonvulsant, and methotrexate.\n8. Participants with Clinically relevant cardiovascular, gastrointestinal, hepatic, neurologic, endocrine, haematologic or other major systemic diseases making implementation of the protocol or other interpretation of the study result difficult\n9. Participants with mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study\n10. Participants with evidence of uncooperative attitude, including poor compliance.\n11. Participants with inability to attend follow-up visit\n12. Participants with any other medical condition (for example uncontrolled infection) that may, in the opinion of the Investigator, interfere with the study objective.\n13. Patients with known hypersensitivity to Ashwagandha.\n14. Patients who had participated in other clinical trials during the previous 3 months.\n15. Patients who have any clinical condition, according to the investigator who does not allow safe fulfilment of clinical trial protocol","45 Years",{"count":415,"type":21},51,[24],"This is a Multi-center, Multi-national, Prospective, Randomized, Double-Blind, Placebo- Controlled three arm study to evaluate the efficacy and safety of Shatavari for the treatment of Menopausal symptoms in Women. Participants will be randomized to either one of the three treatment arms.Participants will then be asked to either take one capsule containing Shatavari or Shatavari + Ashwagandha or Placebo orally once daily in the morning after breakfast with a glass of water for 8 weeks. All the subjects will be asked to continue their routine diet and physical activities during the whole study period. The primary objective is to compare the efficacy of shatavari for treatment of menopausal symptoms in women. The secondary objective is to compare the safety of shatavari for treatment of menopausal symptoms in women.",[419,420,29],"Menopause","Hot Flashes","2024-11-29",{"date":423,"type":37},"2024-12-04",{"date":425,"type":37},"2024-10-26",{"date":427,"type":21},"2025-01-20",{"name":429,"class":430},"SF Research Institute, Inc.","NETWORK",{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":53,"sex":54,"minAge":196,"maxAge":438,"enrollmentInfo":439,"targetDuration":4,"studyType":22,"phases":441,"briefSummary":442,"conditions":443,"keywords":444,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":455},"100541955","student-exercise-and-sleep-timing-study---part-2-100541955","NCT06336590","Student Exercise and Sleep Timing Study - Part 2","SiESTa 2","Inclusion Criteria:\n\n* Healthy undergraduates (18-23 years)\n* Frequent evening exercisers (6pm-11pm, 3+ times per week)\n* Poor self-reported sleep quality\n* Must be willing to wear wrist actigraph 24\u002F7 except when showering\u002Fbathing\n\nExclusion Criteria:\n\n* Sleep\u002Fcircadian rhythm disorders\n* Medications for sleep\n* Inability to change schedule to exercise in AM\n* Inability to maintain exercise frequency over next 4 weeks","23 Years",{"count":440,"type":21},62,[24],"The purpose of this study is to examine the effects of a morning exercise intervention on sleep (quality and duration), mood (positive affect, anxiety, depression, anger), stress and productivity among undergraduate students (18-23 years) evening-exercisers with poor self-reported sleep quality.\n\nAim 1. Compared to the control condition, evening-exercisers prescribed morning exercise will exhibit improved sleep quality (increased efficiency, decreased fragmentation) and increased sleep duration.\n\nAim 2. Compared to the control condition, evening-exercisers prescribed morning exercise will exhibit improved mood (increased positive affect, decreased depression, anxiety and anger).\n\nAim 3. Compared to the control condition, evening-exercisers prescribed morning exercise will exhibit decreased stress and increased productivity.",[133,29,204],[445],"Exercise","2024-11-18",{"date":448,"type":37},"2024-11-21",{"date":450,"type":37},"2024-10-21",{"date":452,"type":21},"2026-12-16",{"name":454,"class":44},"Rutgers, The State University of New Jersey",6,{"id":457,"slug":458,"hasResults":11,"nctId":459,"briefTitle":460,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":53,"sex":16,"minAge":196,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":22,"phases":465,"briefSummary":467,"conditions":468,"keywords":472,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":83},"100443781","phase-4-contraceptive-hormone-and-reward-measurement-charm-study-100443781","NCT05058872","Contraceptive Hormone and Reward Measurement (CHARM Study)","CHARM","Inclusion Criteria:\n\n1. Aged 18 and older;\n2. Right-handed;\n3. Assigned female at birth;\n4. Regular 21-35 day menstrual cycles for the past 6 months per self-report;\n5. In generally good health per self-report. Those with a chronic medical condition may participate at the discretion of the principal investigator if the condition is stable;\n6. Willingness to abstain from intercourse or use a non-hormonal back-up method of contraception (e.g., condoms) during the entire course of the study;\n7. Negative urine drug screen, excepting marijuana or benzodiazepine that is being prescribed by a physician as a sleep aid, assessed at the baseline visit;\n8. Ability to abstain from caffeine and\u002For cannabis for 2 hours prior to functional Magnetic Resonance Imaging (fMRI) scan visits;\n9. Access to a reliable internet connection or cell phone data to complete daily questionnaires;\n10. For those wishing to complete study screening session remotely: access to a reliable internet connection, computer to complete electronic consent and a private space to complete the session.\n\nExclusion Criteria:\n\n1. Presence or history of severe or unstable physical, neurological (per health history interview) or psychiatric disorders (assessed by Miniature International Neuropsychiatric Interview (MINI) but per Diagnostic and Statistical Manual of Mental Disorders - fifth edition (DSM-V) criteria, and the discretion of the principal investigator);\n2. Lifetime history of psychotic disorders;\n3. History of substance use disorder that has not been in remission (as defined by a substance free period of at least one year). However, individuals with mild disorders, disorders solely limited to cannabis, and\u002For those who have achieved close to one year of remission may be eligible at the discretion of the PI;\n4. Presence or history of any category 3 or 4 conditions or medications per the CDC's (Centers for Disease Control and Prevention) Medical Eligibility Criteria for Contraceptive Use pertaining to combined hormonal contraceptive methods as per self-report and reviewed by the principal investigator;\n5. Irregular menstrual periods per self-report;\n6. Any current tobacco smoking (former smokers are eligible so long as their quit date was greater than one year ago);\n7. Any personal or family history of a venous thromboembolism;\n8. Known diagnosis of hypertensive disorder;\n9. Any current or past history of malignancy;\n10. Migraines with aura;\n11. Systolic blood pressure greater than or equal to 140 or diastolic pressure greater than or equal to 90 taken at baseline visit;\n12. Currently nursing an infant;\n13. Known chromosomal or hormonal disorder affecting sex steroids;\n14. Use of hormonal contraceptives currently or in the past 3 months, or use of medications that directly affect sex hormones (i.e. gonadotropin releasing hormone agonists, selective estrogen receptor modifiers);\n15. Current pregnancy or pregnancy\u002Fdelivery in the past six months;\n16. Intention to become pregnant during study participation;\n17. Current use of psychotropic medication;\n18. Claustrophobia;\n19. Metal in body unsafe for magnetic resonance imaging;\n20. Weight over 300 pounds;\n21. Conditions that would make magnetic resonance imaging unsafe for participants (i.e. aneurysm clip, cardiac pacemaker, etc.).",{"count":464,"type":21},144,[466],"PHASE4","Purpose of this study: The purpose of this study is to learn more about how hormonal oral contraceptives affect brain processes and emotional wellbeing.\n\nProcedures: If participants agree to participate, the following will happen:\n\n1. Eligibility visit (remote screening session)\n2. If participants are eligible to participate in the study, they will be placed in one of two groups. If they are in the first group, they will be asked to take an oral contraception pill (\"study drug\") every day for 21 days. If they are in the second, they will take a placebo every day for 21 days. A placebo is a pill that looks like medicine but is not real and will have no medical effect on participants. Participants will not get to choose which group they are in, nor will they be told which group they are in.\n3. During the three-week period in which participants will take either the study drug or placebo, they will be asked to complete daily check-in surveys on their computer or mobile device.\n4. Participants will be asked to attend two additional visits over the course of about three weeks. At these visits, participants will be asked to undergo a urine drug screen, a blood draw, and a magnetic resonance imaging (MRI). They will also be asked to complete behavioral questionnaires.",[469,470,29,471],"Oral Hormonal Contraceptive Use","Neural Activity","Hedonic Function",[473,139,474,475],"oral contraceptives","reward processing","hedonic function","2024-10-31",{"date":478,"type":37},"2024-11-04",{"date":480,"type":37},"2021-10-01",{"date":482,"type":21},"2027-03-31",{"name":484,"class":44},"University of Colorado, Denver",{"id":486,"slug":487,"hasResults":11,"nctId":488,"briefTitle":489,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":53,"sex":54,"minAge":196,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":494,"phases":4,"briefSummary":495,"conditions":496,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":83},"100454453","research-framework-exploring-sleep-health-100454453","NCT05197738","Research Framework Exploring Sleep Health","REFRESH","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Residing within the United States\n* Ability to use the REFRESH app on the participant's own smartphone device\n\nExclusion Criteria:\n\n* In-ability to consent",{"count":493,"type":21},100000,"OBSERVATIONAL","This is a digital health study in which participants are recruited to collect sleep and activity data from digital activity trackers. We are also collecting survey\u002Fquestionnaire data on baseline health and sleep characteristics as well as bi-weekly assessments of sleep quality and mood. Overall, we aim to examine how sleep relates to physical and mental health in a large population of activity tracker users.",[133,497,498,29],"Sleep Apnea","Obesity","2024-06-27",{"date":501,"type":37},"2024-06-28",{"date":503,"type":37},"2022-02-15",{"date":505,"type":21},"2041-12-31",{"name":507,"class":44},"Scripps Translational Science Institute",{"id":509,"slug":510,"hasResults":11,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":514,"eligibilityCriteria":515,"healthyVolunteers":53,"sex":54,"minAge":196,"maxAge":56,"enrollmentInfo":516,"targetDuration":4,"studyType":22,"phases":517,"briefSummary":518,"conditions":519,"keywords":521,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":83},"100536971","psychological-effects-of-a-set-of-essential-oils-100536971","NCT06271759","Psychological Effects of a Set of Essential Oils","Psychological Effects of a Set of Essential Oils - A Randomized Interventional Trial","PSYFRAG","Inclusion Criteria:\n\n* Adults (at least 18 years old)\n\nExclusion Criteria:\n\n* Allergies to Essential Oils\n* Medical conditions that could have an effect on sense of smell",{"count":20,"type":21},[24],"The goal of this clinical trial is to test the effectiveness of an intervention designed to improve wellness through aromatherapy. The main question it aims to answer is whether this intervention can deliver beneficial psychological effects on stress, anxiety and mood, as well as overall well-being.\n\nParticipants will receive a bottle with a no\u002Fneutral odor or an essential oil (or a blend of essential oils) for home administration and will be asked to complete a series of scales pre and post self-administration twice one week apart.",[204,203,520,29],"Well-Being, Psychological",[522,523,100,524,203,204,317],"Fragrances","Essential Oils","Psychological effects","2024-06-19",{"date":527,"type":37},"2024-06-24",{"date":529,"type":37},"2024-04-04",{"date":531,"type":21},"2024-11-15",{"name":533,"class":44},"University of Bucharest",{"id":535,"slug":536,"hasResults":11,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":53,"sex":54,"minAge":196,"maxAge":541,"enrollmentInfo":542,"targetDuration":4,"studyType":22,"phases":544,"briefSummary":545,"conditions":546,"keywords":550,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":83},"100357561","phase-2-acute-effects-of-stimulant-medication-in-college-students-with-adhd-100357561","NCT03935646","Acute Effects of Stimulant Medication in College Students With ADHD","Acute Effects of Prescription Stimulant Medication on Cognition and Mood in College Students With and Without ADHD","Inclusion Criteria:\n\n* Be currently enrolled either full time or part time as an undergraduate in a 2-year or 4-year college\n* Be between the ages of 18-29\n* Be a native English speaker\n* ADHD Participants: Must report a prior diagnosis of ADHD and self-report five or more inattention (IA) symptoms on the DSM-5 Symptom Checklist on the pre-screener.\n* Healthy Participants: Must disavow ever being diagnosed with ADHD, report 3 or fewer IA symptoms and 3 or fewer hyperactivity\u002Fimpulsivity (HI) symptoms on the DSM-5 ADHD Symptom Checklist in the pre-screener and are an age and sex match of an ADHD group participant\n\nExclusion Criteria:\n\n* Not meeting any of the above stated inclusion criteria\n* Any contraindications for physical exercise placing the participant at moderate or high-risk. This includes the following:\n\n  1. Participants will be excluded if they report having an acute or uncontrolled disease (cardiovascular, pulmonary, neurological, endocrine, musculoskeletal, immunological).\n  2. Participants will be excluded if they are non-ambulatory or rely on walking aids for ambulation.\n  3. Participants will be excluded who chronically manage asthma or another respiratory condition or require using an inhaler to complete exercise.\n  4. Participants will be excluded if they experience uncontrolled or current problems with syncope (loss of consciousness or fainting) or postural hypotension.\n  5. Participants will be excluded if they have ever had a stroke, aneurysm, or transient ischemic attack (TIA).\n  6. Participants will be excluded if they have exercise or physical activity restrictions imposed by a health provider.\n  7. Participants will be excluded by the medical director due to possible underlying disease\u002Fcondition or risk.\n  8. Participants will be excluded if they are pregnant (determined by a urine pregnancy test), are attempting to become pregnant, or are currently breastfeeding will also be excluded (stated above).\n  9. Participants will be excluded for any current use of other psychotropic drugs (e.g., SSRIs, SNRIs, sedatives; stated above).\n* Any contraindications for stimulant medication use placing the participant at moderate or high-risk. This includes the following:\n\n  1. Participants will be excluded if they have ever been diagnosed with seizure disorder, high blood pressure, glaucoma, gastrointestinal hypermotility disorder (e.g., IBS), diabetes, hypoglycemia, cardiac problems (e.g., heart disease), or thyroid problems.\n  2. Participants will be excluded if they have ever been diagnosed with a bipolar disorder (e.g., Bipolar I or Bipolar II), a psychotic disorder (e.g., schizophrenia), a sleep disorder (e.g., narcolepsy), an eating disorder (e.g., bulimia nervosa), or a severe substance use disorder (e.g., endorsing six or more symptoms of a substance use disorder according to the DSM-5). Participants will also be excluded if they report a past year diagnosis of major depressive disorder, panic disorder, generalized anxiety disorder, or any substance use disorder.\n  3. Participants will be excluded if they report any prior treatment for substance use (e.g. rehabilitation for alcohol or other substance use). Additionally, participants will be excluded if they do not agree to abstain from illicit or addictive drugs and marijuana use for the duration of the study beginning with the eligibility assessment.\n  4. Participants will be excluded if they experience uncontrolled or current problems with syncope (e.g., loss of consciousness or fainting) or postural hypotension.\n  5. Participants will be excluded if they are pregnant (determined by a urine pregnancy test), are attempting to become pregnant, or are currently breastfeeding.\n  6. Non-ADHD participants will be excluded if they have ever engaged in non-prescription stimulant use.\n  7. ADHD participants who are currently prescribed a prescription stimulant will be asked not to take their medication the day prior to and day of any study visits. They will be excluded if they are not comfortable with abstaining.\n  8. Participants will be excluded for any current use of other psychotropic drugs (e.g., SSRIs, SNRIs, sedatives) or non-stimulant ADHD medication (i.e., Strattera).\n  9. Participants will be excluded for any current use of any other prescription medication that could interact negatively with Adderall (e.g., neurological and blood-pressure drugs, antihistamines).\n  10. They will also be excluded for current use of high levels of caffeine consumption (e.g., daily use more than 600mg\u002Fday or about six 8-oz. cups of coffee). Daily use is defined as 5 or more days per week for the last month.\n  11. Participants who are using other over-the-counter-substances that could interact negatively with Adderall (e.g., dietary supplements, weight-loss pills, and low-to-moderate levels of caffeine consumption, antihistamines) will be asked to abstain from use for at least 12-hours prior to lab visits. They will be excluded if they are not comfortable with abstaining.\n  12. Participants will be excluded if they report current nicotine use (i.e., 5 or more cigarettes per day), daily vaping (i.e., e-cigarettes), smokeless tobacco (i.e., chewing tobacco), nicotine gum, and\u002For nicotine patches use in the past month.\n  13. Participants will be excluded if they experienced a concussion within the past 6 months, have experienced two or more concussions in their lifetime, or have a history of traumatic brain injury.\n  14. Participants will be excluded if they have ever had a stroke, aneurysm, or transient ischemic attack (TIA).\n  15. Participants will be excluded if they are unwilling to ingest a prescription stimulant medication (Adderall) or placebo in the lab.","29 Years",{"count":543,"type":21},40,[61],"The investigators will examine the acute effects of stimulant medication on executive functioning. The rationale for the proposed study is to examine the efficacy of stimulants for college students with ADHD and help prevent stimulant misuse among college students without ADHD. The working hypothesis is that stimulants, compared to baseline and placebo conditions, will improve executive functioning for college students with ADHD but not for college students without ADHD. Improvements on executive functioning measures (e.g., CPT-IP, Spatial Span) will be examined through 2 (ADHD vs. non-ADHD) x 3 (Baseline, Placebo, Stimulant) repeated measures ANOVAs. Follow-up analyses will include paired comparisons.\n\nExpected outcomes are to confirm these hypotheses and demonstrate the need for further study of stimulants. If confirmed, the results will provide pilot data for a larger NIH grant proposal aimed at further examining the acute effects of stimulants (i.e., improved cognitive functioning with stimulants) and comparing them to the acute effects of physical exercise (i.e., improved cognitive functioning immediately after exercise). The investigators expect this outcome to have an important positive impact because it can help support stimulant medication as an effective treatment for college students with ADHD (DuPaul et al., 2012). Additionally, demonstration that stimulants do not improve executive functioning for college students without ADHD can be used to help prevent and discourage stimulant misuse and diversion on college campuses (Hartung et al., 2013).",[547,548,267,549,29],"Attention Deficit Hyperactivity Disorder","Stimulant Use","Change in Sustained Attention",[547,548,267,549,29],"2024-06-07",{"date":553,"type":37},"2024-06-10",{"date":555,"type":37},"2020-02-11",{"date":557,"type":21},"2025-06-30",{"name":559,"class":44},"University of Wyoming"]